Australia's most trusted
source of pharma news
Sunday, 31 August 2025
Posted 4 August 2025 AM
The TGA has approved a next-generation ROS1 tyrosine kinase inhibitors targeting lung cancer, catching up with the PBAC recommendation.
BMS's Augtyro was listed on the ARTG on 25 July, indicated for the treatment of adult patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.